IL303288A - N,N-Dimethyltryptamine compounds partially or fully deuterated - Google Patents
N,N-Dimethyltryptamine compounds partially or fully deuteratedInfo
- Publication number
- IL303288A IL303288A IL303288A IL30328823A IL303288A IL 303288 A IL303288 A IL 303288A IL 303288 A IL303288 A IL 303288A IL 30328823 A IL30328823 A IL 30328823A IL 303288 A IL303288 A IL 303288A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- formula
- hydroxy
- pharmaceutically acceptable
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/108,938 US20220169606A1 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| GBGB2018955.1A GB202018955D0 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| GB2103981.3A GB2605144A (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| US17/208,583 US11773062B2 (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| PCT/EP2021/060750 WO2021116503A2 (en) | 2020-06-02 | 2021-04-23 | Deuterated compounds |
| GB2106881.2A GB2595776B (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| PCT/EP2021/062794 WO2021244831A1 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| CA3118556A CA3118556A1 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| US17/320,155 US12042564B2 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| PCT/EP2021/082227 WO2022117359A1 (en) | 2020-12-01 | 2021-11-18 | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL303288A true IL303288A (en) | 2023-07-01 |
Family
ID=88294961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL303288A IL303288A (en) | 2020-12-01 | 2021-11-18 | N,N-Dimethyltryptamine compounds partially or fully deuterated |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP4275753B1 (https=) |
| JP (1) | JP7834754B2 (https=) |
| CN (1) | CN116761599B (https=) |
| AU (1) | AU2021391581A1 (https=) |
| CA (1) | CA3203020A1 (https=) |
| IL (1) | IL303288A (https=) |
| TW (1) | TWI891942B (https=) |
| WO (1) | WO2022117359A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| CN114787363A (zh) | 2019-10-01 | 2022-07-22 | 恩派瑞安神经科学公司 | 对真菌进行遗传工程化以调节色胺表达 |
| JP7422473B2 (ja) | 2019-11-07 | 2024-01-26 | サイビン ユーケー リミテッド | 合成方法 |
| PH12022551981A1 (en) | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| MX2024005955A (es) * | 2021-11-18 | 2024-06-11 | Cybin Uk Ltd | Formulaciones inyectables e inhalables. |
| EP4457336A4 (en) | 2021-12-31 | 2026-01-14 | Empyrean Neuroscience Inc | ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS |
| US20250051279A1 (en) * | 2022-01-14 | 2025-02-13 | Cybin Irl Limited | Tryptamine compositions and methods |
| US12264131B2 (en) * | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| CN120344243A (zh) | 2022-10-13 | 2025-07-18 | 赛本英国有限公司 | 包含致幻剂的胃肠外制剂的施用方法 |
| EP4618981A1 (en) | 2022-11-17 | 2025-09-24 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
| WO2024156713A1 (en) | 2023-01-23 | 2024-08-02 | Cybin Uk Ltd | Treatment of psychiatric or neurological disorders by parenteral administration of a single, effective parenteral dose of a short-acting psychedelic agent |
| AU2024242138A1 (en) | 2023-03-31 | 2025-11-13 | Cybin Uk Ltd | Combination comprising a monoamine antidepressant agent and a short-duration psychedelic agent |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2026013174A1 (en) | 2024-07-10 | 2026-01-15 | Cybin Uk Ltd | Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002520353A (ja) * | 1998-07-16 | 2002-07-09 | マサチューセッツ インスティテュート オブ テクノロジー | ストレスの処置のための組成物 |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| PH12022551981A1 (en) * | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| WO2021234608A1 (en) * | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| AU2021204158B2 (en) * | 2020-06-02 | 2023-03-02 | Cybin Uk Ltd | Deuterated compounds |
| EP3902541B1 (en) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US11000534B1 (en) * | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2021
- 2021-11-18 IL IL303288A patent/IL303288A/en unknown
- 2021-11-18 CA CA3203020A patent/CA3203020A1/en active Pending
- 2021-11-18 JP JP2023533243A patent/JP7834754B2/ja active Active
- 2021-11-18 AU AU2021391581A patent/AU2021391581A1/en active Pending
- 2021-11-18 CN CN202180090269.1A patent/CN116761599B/zh active Active
- 2021-11-18 EP EP23198784.3A patent/EP4275753B1/en active Active
- 2021-11-18 WO PCT/EP2021/082227 patent/WO2022117359A1/en not_active Ceased
- 2021-11-18 TW TW110143066A patent/TWI891942B/zh active
- 2021-11-18 EP EP21815486.2A patent/EP4031529B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7834754B2 (ja) | 2026-03-24 |
| CA3203020A1 (en) | 2022-06-09 |
| EP4275753B1 (en) | 2026-03-18 |
| JP2023551058A (ja) | 2023-12-06 |
| CN116761599B (zh) | 2025-05-30 |
| EP4031529C0 (en) | 2023-09-27 |
| CN116761599A (zh) | 2023-09-15 |
| EP4275753A2 (en) | 2023-11-15 |
| TWI891942B (zh) | 2025-08-01 |
| WO2022117359A1 (en) | 2022-06-09 |
| EP4275753A3 (en) | 2023-12-27 |
| AU2021391581A1 (en) | 2023-07-06 |
| EP4031529B1 (en) | 2023-09-27 |
| EP4031529A1 (en) | 2022-07-27 |
| TW202237565A (zh) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL303288A (en) | N,N-Dimethyltryptamine compounds partially or fully deuterated | |
| EP0406274B1 (en) | Water soluble, antineoplastic derivatives of taxol | |
| CA2178161C (en) | Indole derivatives | |
| IL292753B2 (en) | Compounds, compositions comprising same, and uses thereof in the treatment of psychiatric or neurological disorders | |
| JPWO2022000091A5 (https=) | ||
| JP2006502143A5 (https=) | ||
| CN1615861A (zh) | （1s，2s）－1－（4－羟基苯基）－2－（4－羟基－4－苯基哌啶－1－基）－1－丙醇甲磺酸盐三水合物 | |
| WO1997037989A1 (en) | Indole derivatives as 5-ht receptor antagonist | |
| JP2007508361A5 (https=) | ||
| KR100878416B1 (ko) | 피페라진 화합물 | |
| CN1141916A (zh) | 取代哌啶衍生物和含它们的药物 | |
| JPWO2022117359A5 (https=) | ||
| JP2006522141A5 (https=) | ||
| KR930702334A (ko) | 5 하이드록시트립타민 수용체 길항제로서의 인돌우레아 | |
| JP2006512293A (ja) | ＩｇＥを調節し、細胞増殖を阻害するためのフェニル−インドール化合物 | |
| US6429312B2 (en) | N-aminoalkyldibenzothiopencarboxamide receptor subtype specific ligands | |
| EP0233762B1 (en) | Use of aromatic diamines for the treatment of angina pectoris, and diamines therefor | |
| NO20060428L (no) | 2-amino-bicyklo[3.1.0]heksan-2,6-dikarboksylesterderivat | |
| IL95250A (en) | 1-(pyridinylamino)-2-pyrrolidinones, a process for their preparation and their use as medicaments | |
| TWI225856B (en) | Amide compounds | |
| CN110845408A (zh) | 同位素富集的乐伐替尼 | |
| CA2483345A1 (en) | Imidazolinylmethyl aralkylsulfonamides | |
| WO2023022231A1 (ja) | ウイルス感染症を処置または予防するための可逆的共有結合阻害物質 | |
| JPH05504954A (ja) | 新規なβ―フエニルイソセリン誘導体、それの製造およびそれの使用 | |
| CA2299400C (en) | Method for treating disease-related or drug-induced dyskinesias |